Safety of Avacopan for the Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Combined Data From Three Clinical Trials
In clinical trials of GPA or MPA, use of avacopan was associated with fewer AEs, SAEs, and WBC count reductions and fewer infections than non-avacopan treatment. Safety data support the use of avacopan in patients with GPA or MPA.
Authors
- Andreas Kronbichler (ORCID: https://orcid.org/0000-0002-2945-2946)
- Michael George (ORCID: https://orcid.org/0000-0002-0398-2308)
- David R.W. Jayne (ORCID: https://orcid.org/0000-0002-1712-0637)
- Tamara Popov
- Peter A. Merkel (ORCID: https://orcid.org/0000-0001-9284-7345)
- Huibin Yue
Institutions
- Amgen (United States) (US)
- Universität Innsbruck (AT)
- Trinity College Dublin (IE)
- University of Cambridge (GB)
- Vifor Pharma (Switzerland) (CH)
- University of Pennsylvania (US)
- Philadelphia University (US)
Publication Details
- Journal
- ACR Open Rheumatology
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/acr2.70001
- Citations
- 10
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 15.18